Taysha Gene Therapies (TSHA) vs Vericel (VCEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Vericel (VCEL) has outperformed Taysha Gene Therapies (TSHA) over the past year, gaining 17.3% versus a loss of 6.1%. Over five years, VCEL leads with a -19.8% price change compared with -75.2% for TSHA. Vericel is the larger company by market cap ($2.05 billion vs $1.44 billion), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TSHA | VCEL |
|---|---|---|
| Share price | $4.43 | $40.05 |
| Market cap | $1.44B | $2.05B |
| 1-day change | 0.00% | -1.69% |
| YTD return | -19.45% | +11.22% |
| 1-year return | -6.14% | +17.35% |
| 5-year return | -75.22% | -19.79% |
| P/E ratio (TTM) | — | 85.21 |
| Forward P/E | — | 47.34 |
| EPS (TTM) | $-0.41 | $0.47 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.30 | $49.32 |
| 52-week low | $3.69 | $28.95 |
| Distance from 52-week high | -39.32% | -18.80% |
| Analyst consensus | none | none |
| Avg. price target upside | +193.45% | +51.24% |
| Average volume | 3.28M | 502.23K |
| Shares outstanding | 325.83M | 51.21M |
| Employees | 99 | 398 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VCEL has outperformed TSHA by 23.5 percentage points over the past year.
About Taysha Gene Therapies
TSHA stock →Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome.
Healthcare · Biotechnology · 99 employees
About Vericel
VCEL stock →Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns.
Healthcare · Biotechnology · 398 employees
TSHA vs VCEL FAQ
Which is bigger, Taysha Gene Therapies or Vericel?
Vericel (VCEL) is larger, with a market capitalization of $2.05B compared with $1.44B for Taysha Gene Therapies (TSHA).
Which stock has performed better over the past year, TSHA or VCEL?
VCEL returned +17.35% over the past 12 months, compared with -6.14% for TSHA (price return, excluding dividends). Past performance does not predict future results.
Are Taysha Gene Therapies and Vericel in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.